Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propyphenazone is a small molecule non-steroidal anti-inflammatory drug (NSAID) of the pyrazolone class, structurally related to phenazone. It acts as an analgesic and antipyretic with some anti-inflammatory activity, primarily used for the treatment of pain and fever, such as headache and toothache. Its mechanism of action involves inhibition of cyclooxygenase enzymes (COX), leading to reduced synthesis of prostaglandins responsible for pain, inflammation, and fever[1][3][7][8]. Propyphenazone is often marketed in combination with paracetamol and caffeine for primary headache disorders[4]. It was introduced in 1951 for rheumatic disorders but has since seen restricted use or bans in some countries due to safety concerns such as blood dyscrasias and rare cardiovascular events[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propyphenazone.